47 results
8-K
EX-99.2
EBS
Emergent Biosolutions Inc
1 May 24
Emergent Biosolutions Reports First Quarter 2024 Financial Results
4:44pm
is unchanged Q1 stabilization efforts and priorities: Continued focus on MCM and NARCAN® Nasal Spray as core business drivers Strengthened engagement … government opportunities ◦ Focus on EU-level stockpiling approach for MCMs to be used in health emergencies ◦ HERA engagement and collaboration
8-K
EX-99.2
EBS
Emergent Biosolutions Inc
6 Mar 24
Emergent Biosolutions Reports Fourth Quarter 2023 Financial Results
4:15pm
months we will strengthen engagement across internal and external stakeholders around our mission to protect and enhance lives. 2024 & 2025 focused
8-K
EX-10.1
woqdxs5oaptkv c6o
17 May 23
Emergent’s Statement Regarding its Amended Credit Agreement
9:32pm
8-K
EX-10.2
rhpx bsjllpk72
17 May 23
Emergent’s Statement Regarding its Amended Credit Agreement
9:32pm
DEFR14A
rxaur 5wi
24 Apr 23
Revised proxy
9:32am
8-K
EX-99.2
qwpg 3jxzarw0qbr
13 Jan 20
Emergent Biosolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast
6:43am
8-K
EX-99
4vd7sikpvrtwvpegf4bb
21 Nov 19
Emergent Biosolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day
4:23pm
8-K
EX-99.1
cl2xff93
4 Jan 19
Departure of Directors or Certain Officers
7:13am